GHK-Cu got a national radio segment this morning, and the framing was the one the compound has never been able to shake: the topical file is thick, the injectable file is empty, and the market moved anyway. NPR's Will Stone published "The copper peptide trend has gone from creams to injections — ahead of the science" on September 7, quoting three dermatologists and a University of Washington aging researcher who has spent years studying the molecule in mice.
Nothing in the piece is new evidence. What it is, is the first time the topical-versus-injectable split that anyone reading GHK-Cu vendor pages already knows about has been laid out for a general audience — five months before the FDA committee that could change the legal status of injectable GHK-Cu sits down to review it. The timing is the story.
Research-context information only. GHK-Cu is a research peptide; topical copper-peptide cosmetics are a separate regulatory category not addressed by this coverage. Protocols, doses, and reactions reported below come from published research, public FDA records, and named journalistic sourcing. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What NPR reported
Stone's segment traces GHK back to chemist Loren Pickart, who isolated the tripeptide in the early 1970s after noticing that liver cells bathed in plasma from younger adults behaved like younger cells. Pickart then compared blood from medical students against blood from older professors and established the age curve the compound is still known for — serum GHK averaging around 200 ng/mL at age 20 and roughly 80 ng/mL by 60.
The four sources quoted split cleanly along the route of administration.
| Source | Affiliation | Position as quoted |
|---|---|---|
| Dr. David Goldberg | Schweiger Dermatology / Icahn School of Medicine at Mount Sinai | "The science behind this is very solid" — and separately, "I'm not going to sleep well at night, until the human studies are actually done" |
| Dr. Warren Ladiges | University of Washington School of Medicine | "I think GHK can have a major role in helping enhance longevity. But injecting yourself without really knowing what it's going to do? I wouldn't do that to myself" |
| Dr. Marisa Garshick | MDCS Dermatology | "Whether or not it's even a copper peptide is always a concern. The stakes are much higher when you're injecting something" |
| Erik Marks | Vitality Medical PNW, Seattle | On patients arriving mid-protocol: "They haven't been checking lab work or anything" |
Marks, who runs a wellness clinic, gave the piece its only clinical observations: injection-site irritation and infections at the mild end, and elevated liver enzymes and elevated serum copper in people who had been injecting heavily without any lab monitoring. Those are observations from one practice, not a case series, and NPR presented them as such.
On the regulatory side the piece states two things worth writing down precisely. Compounding pharmacies in the United States cannot currently prepare GHK-Cu for human injection. And an FDA advisory panel that recommended reclassifying roughly six peptides earlier this year will reconvene in February to take up the evidence for GHK-Cu as an injectable.
The split NPR described, in citations
The asymmetry is real and it is easy to see once the papers are lined up by route rather than by compound.
Topical. Controlled human work exists and predates the current wave by decades. Maquart and colleagues established collagen-synthesis stimulation by the tripeptide-copper complex in fibroblast culture in FEBS Letters in 1988 (PMID 3169264). Leyden and colleagues ran topical copper tripeptide on CO2 laser-resurfaced skin in Archives of Facial Plastic Surgery in 2006 (PMID 16847171). Pickart and Margolina's 2015 BioMed Research International review consolidates the skin-regeneration pathway work (PMID 26236730), and their 2018 IJMS paper covers the gene-expression data (PMID 29986520). NPR's characterisation of those trials as small and often cosmetic-industry-funded is accurate; they are also real controlled trials in humans, which is more than most compounds in this channel can say.
Injected. No published human trial, for any endpoint. The systemic file is animal work: intraperitoneal GHK-Cu against bleomycin-induced pulmonary fibrosis in mice (PMID 31809714), and intra-articular GHK-Cu in a rat ACL-reconstruction model, where the healing benefit was explicitly described by the authors as transient (PMID 25731775).
Ladiges' own line of work sits in that second column. His group's review of GHK as an anti-aging peptide appeared in Aging Pathobiology and Therapeutics in 2020 (PMID 35083444), and a 2026 preprint from that literature compared intraperitoneal against intranasal GHK-Cu in aged mice, reporting behavioural rescue by both routes but divergent hippocampal aging programs between them. That last detail is the one worth holding onto: in the only recent work that directly compared two systemic routes, the routes did not produce the same tissue-level result. Route is not a formality.
We laid the same split out compound-by-compound, with penetration coefficients and per-outcome cost, in GHK-Cu topical vs injectable. Nothing in the NPR piece changes what is in it.
The February panel is the part with consequences
The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 and voted narrowly to recommend adding six peptides — BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax — to the 503A Bulk Drug Substances List, over the objections of the agency's own reviewers. We covered that vote and its limits in the PCAC outcome breakdown.
GHK-Cu was not on that agenda. It is on the next one. The FDA has said a second session will convene before the end of February 2027 covering five substances: GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF — the lineup we broke down in the second-panel preview. NPR's "February" reference is that session.
What a favorable vote would and would not do:
- Would: open a legal path for 503A compounding pharmacies to prepare injectable GHK-Cu against an individual prescription — the exact thing they cannot do today.
- Would not: happen quickly. PCAC recommends; the FDA rules afterward through notice-and-comment rulemaking that runs well past the vote.
- Would not: approve GHK-Cu as a drug, change how research-channel vials are sold, or generate the human safety data every clinician in the NPR piece said was missing.
The research channel is not waiting on any of that, and has not been. What the February session actually decides is whether a second, prescription-based supply route opens alongside it.
What this changes for someone buying today
Practically: nothing about availability, and one thing about scrutiny.
Garshick's concern in the piece — "whether or not it's even a copper peptide is always a concern" — is an identity-and-purity question, and it is the one question in this whole story that the market already has a mechanism for. Batch-level certificates of analysis showing identity by mass spectrometry, purity by HPLC, and endotoxin and sterility results are standard among the vendors we rank, and the lot number on the COA is supposed to match the lot number on the vial. That match is the entire point. Vendor-by-vendor COA practice, price per mg and current coupon status are compared in the GHK-Cu buying guide, and live across recommended vendors on the GHK-Cu comparison page.
The second thing the NPR piece surfaces is measurement. Marks described patients whose copper and liver enzymes had drifted while nobody was looking. Serum copper and ceruloplasmin are the direct markers; ALT and AST cover the hepatic signal. Those are ordinary outpatient labs, and the panel with reported reference ranges is set out in GHK-Cu bloodwork and biomarkers. The people in that clinician's account were not people who tested and got a bad result — they were people who had run months of protocol with no baseline at all.
